Ha habido 48 transacciones internas recientes registradas para BeOne Medicines Ltd. (ONC), incluyendo 14 compras y 31 ventas. El total de compras internas fue valorado en $20.15M y el total de ventas internas en $21.34M.
Internos destacados con actividad reciente incluyen Lee Chan Henry, Oyler John, Wu Xiaobin. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — ONC
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-03-11 |
Lee Chan Henry |
SVP, General Counsel |
Venta Informativa |
341 |
$300.00 |
$102.3K |
- |
| 2026-03-06 |
Oyler John |
Chief Executive Officer |
Concesión de RSU |
326,976 |
- |
- |
5,491,339 |
| 2026-03-06 |
Wu Xiaobin |
President and COO |
Concesión de RSU |
168,922 |
- |
- |
1,137,900 |
| 2026-03-06 |
Wang Lai |
President, Global Head of R&d |
Concesión de RSU |
112,606 |
- |
- |
1,564,030 |
| 2026-03-06 |
Lee Chan Henry |
SVP, General Counsel |
Concesión de RSU |
65,390 |
- |
- |
288,496 |
| 2026-03-06 |
Rosenberg Aaron |
Chief Financial Officer |
Concesión de RSU |
79,014 |
- |
- |
294,346 |
| 2026-02-04 |
Lee Chan Henry |
SVP, General Counsel |
Venta Informativa |
996 |
$350.00 |
$348.6K |
- |
| 2026-01-07 |
Lee Chan Henry |
SVP, General Counsel |
Venta Informativa |
664 |
$331.76 |
$220.29K |
- |
| 2025-12-31 |
Wang Lai |
President, Global Head of R&d |
Concesión de RSU |
427,895 |
- |
- |
1,451,424 |
| 2025-12-16 |
Oyler John |
Chief Executive Officer |
Venta Informativa |
40 |
$305.24 |
$12.21K |
- |
| 2025-12-15 |
Oyler John |
Chief Executive Officer |
Venta Informativa |
1,194 |
$314.92 |
$376.01K |
24,369 |
| 2025-12-11 |
Lee Chan Henry |
SVP, General Counsel |
Venta Informativa |
332 |
$325.00 |
$107.9K |
- |
| 2025-12-10 |
Lee Chan Henry |
SVP, General Counsel |
Venta Informativa |
332 |
$318.28 |
$105.67K |
- |
| 2025-11-26 |
Sanders Corazon (corsee) D. |
Director |
Venta Informativa |
804 |
$342.47 |
$275.35K |
- |
| 2025-11-17 |
Wu Xiaobin |
President and COO |
Venta Informativa |
10 |
$382.32 |
$3.82K |
- |
| 2025-11-13 |
Wu Xiaobin |
President and COO |
Venta Informativa |
1,769 |
$381.05 |
$674.08K |
- |
| 2025-11-12 |
Oyler John |
Chief Executive Officer |
Donación (Otorgada) |
858,533 |
- |
- |
6,441,041 |
| 2025-11-12 |
Wu Xiaobin |
President and COO |
Venta Informativa |
154 |
$362.07 |
$55.76K |
6,009 |
| 2025-11-12 |
Lee Chan Henry |
SVP, General Counsel |
Venta Informativa |
332 |
$350.00 |
$116.2K |
- |
| 2025-11-11 |
Oyler John |
Chief Executive Officer |
Donación (Otorgada) |
151,320 |
- |
- |
7,299,574 |
| 2025-11-07 |
Wang Xiaodong |
Other: Chair, Scientific Advisory Brd |
Donación (Otorgada) |
424,073 |
- |
- |
4,582,601 |
| 2025-10-08 |
Lee Chan Henry |
SVP, General Counsel |
Ejercicio de Opciones |
296 |
$159.03 |
$47.07K |
9,559 |
| 2025-06-24 |
Wang Xiaodong |
Other: Chair, Scientific Advisory Brd |
Venta Informativa |
100 |
$267.81 |
$26.78K |
- |
| 2025-06-23 |
Oyler John |
Chief Executive Officer |
Venta Informativa |
100 |
$262.90 |
$26.29K |
- |
| 2025-06-23 |
Wu Xiaobin |
President and COO |
Venta Informativa |
1,363 |
$260.00 |
$354.38K |
- |
| 2025-06-23 |
Wang Lai |
Global Head of R&d |
Venta Informativa |
1,028 |
$260.00 |
$267.28K |
- |
| 2025-06-17 |
Oyler John |
Chief Executive Officer |
Venta Informativa |
1,460 |
$256.49 |
$374.47K |
- |
| 2025-06-17 |
Wu Xiaobin |
President and COO |
Venta Informativa |
630 |
$250.87 |
$158.05K |
- |
| 2025-06-17 |
Wang Lai |
Global Head of R&d |
Venta Informativa |
470 |
$251.37 |
$118.14K |
- |
| 2025-06-16 |
Oyler John |
Chief Executive Officer |
Venta Informativa |
3,680 |
$266.05 |
$979.05K |
1,460 |
| 2025-06-16 |
Wu Xiaobin |
President and COO |
Venta Informativa |
100 |
$266.22 |
$26.62K |
630 |
| 2025-06-16 |
Wang Lai |
Global Head of R&d |
Venta Informativa |
1,177 |
$266.40 |
$313.56K |
470 |
| 2025-06-16 |
Lee Chan Henry |
SVP, General Counsel |
Venta Informativa |
422 |
$266.50 |
$112.46K |
- |
| 2025-06-11 |
Ball Titus B. |
Principal Accounting Officer |
Venta Informativa |
134 |
$258.36 |
$34.62K |
- |
| 2025-06-10 |
Oyler John |
Chief Executive Officer |
Concesión de RSU |
348,374 |
$20.26 |
$7.06M |
348,374 |
| 2025-06-10 |
Yi Qingqing |
Director |
Otro (Venta) |
29,614 |
- |
- |
27,326 |
| 2025-06-10 |
Wang Xiaodong |
Other: Chair, Scientific Advisory Brd |
Venta Informativa |
100 |
$264.85 |
$26.49K |
- |
| 2025-06-10 |
Ball Titus B. |
Principal Accounting Officer |
Concesión de RSU |
29,601 |
- |
- |
73,983 |
| 2025-06-10 |
Wu Xiaobin |
President and COO |
Concesión de RSU |
232,245 |
$20.26 |
$4.71M |
232,245 |
| 2025-06-10 |
Wang Lai |
Global Head of R&d |
Concesión de RSU |
162,565 |
$20.26 |
$3.29M |
162,565 |
| 2025-06-10 |
Lee Chan Henry |
SVP, General Counsel |
Concesión de RSU |
88,244 |
$20.26 |
$1.79M |
88,244 |
| 2025-06-10 |
Rosenberg Aaron |
Chief Financial Officer |
Concesión de RSU |
119,873 |
$20.26 |
$2.43M |
119,873 |
| 2025-06-06 |
Oyler John |
Chief Executive Officer |
Venta Informativa |
400 |
$255.74 |
$102.3K |
- |
| 2025-06-06 |
Wu Xiaobin |
President and COO |
Venta Informativa |
234 |
$255.77 |
$59.85K |
- |
| 2025-06-06 |
Wang Lai |
Global Head of R&d |
Venta Informativa |
300 |
$255.30 |
$76.59K |
- |
| 2025-06-06 |
Lee Chan Henry |
SVP, General Counsel |
Venta Informativa |
230 |
$256.79 |
$59.06K |
- |
| 2025-05-21 |
Baker Bros. Advisors Lp |
Director |
Concesión de RSU |
45,500 |
$18.19 |
$827.65K |
45,500 |
| 2025-02-28 |
Baker Bros. Advisors Lp |
Director |
Venta Informativa |
60,851 |
$260.00 |
$15.82M |
730,642 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
